Related Experiment Video
Updated: Jul 28, 2026
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Reasons for optimism in the search for new vaccines for tuberculosis
1Vaccitech,Oxford,UK.
Abstract:
In the development of vaccines for tuberculosis (TB), the combination of the will, funding, scientific rigor, new tools, refined animal models and improved clinical trial designs are all converging at an opportune moment. The lack of optimism that has surrounded the likelihood for finding novel TB vaccines has resulted from a lack of correlates of vaccine-induced protection, a lack of tool candidate vaccines to probe the immunologic space, which may be needed, and the negative result of one recent trial. A vaccine for TB that can be delivered at a reasonable cost to the marketplace will have greater impact on the incidence of new cases of TB than any intervention in world history. Now is the time to increase resources, both financial and human intellectual capacity, for a global tuberculosis vaccine effort.
Insights
Developing new tuberculosis (TB) vaccines is crucial. Increased global resources and scientific collaboration are needed now to overcome past challenges and create effective TB vaccines.
Area of Science:
- Immunology
- Vaccinology
- Infectious Diseases
Background:
- Tuberculosis (TB) remains a significant global health challenge.
- Past efforts to develop effective TB vaccines have faced hurdles, including a lack of clear protection markers and candidate vaccines.
- A recent clinical trial yielded disappointing results, impacting optimism.
Purpose of the Study:
- To highlight the converging factors supporting a renewed global effort in TB vaccine development.
- To emphasize the critical need for increased investment and scientific focus on novel TB vaccines.
Main Methods:
- This abstract does not detail specific experimental methods.
- It synthesizes the current landscape of TB vaccine research and development.
Main Results:
- Despite past setbacks, key elements for progress are aligning: scientific will, funding, rigor, new technologies, better animal models, and improved clinical trial designs.
- A cost-effective TB vaccine could dramatically reduce global TB incidence.
Conclusions:
- The convergence of resources and scientific advancements presents an opportune moment for TB vaccine development.
- Increased financial and intellectual investment in a global TB vaccine initiative is urgently required.
Related Concept Videos
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:23Tuberculosis